Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.06.2012 | short review

Advanced breast cancer: new imaging techniques for detection of metastases

verfasst von: Helmut Schoellnast, MD, Christian Gstettner, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Whole-body imaging modalities such as [18F]fluorodeoxyglucose (FDG)—positron emission tomography (PET)/CT or whole-body MRI (WB-MRI) appear as new promising tools to detect tumor recurrence or distant metastases. Both techniques expect to have some impact on patient management. In order to detect bone metastases, [18F]fluoride-PET/CT and SPECT/CT are further new imaging tools. This review article provides an overview over the accuracy of these imaging techniques in staging of breast cancer.
Vorheriger Artikel Breast cancer: is there a need for biopsy of metastases?
Nächster Artikel Treatment outcome in AML: a single-centre experience in an unselected patient cohort
Literatur
1.
Pennant M, Takwoingi Y, Pennant L, et al. A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. Health Technol Assess. 2010;14:1–103.
2.
Anonymous. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators. JAMA. 1994;271:1587–92.
3.
Palli D, Russo A, Saieva C, et al. Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. National Research Council project on breast cancer follow-up. JAMA. 1999;281:1586.CrossRefPubMed
4.
Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council project on breast cancer follow-up. JAMA. 1994;271:1593–97.CrossRefPubMed
5.
Rojas MP, Telaro E, Russo A, Moschetti I, Coe L, Fossati R, et al. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001768 (Review).
6.
Piperkova E, Raphael B, Altinyay ME, et al. Impact of PET/CT in comparison with same day contrast enhanced CT in breast cancer management. Clin Nucl Med. 2007;32:429–34.CrossRefPubMed
7.
Veit-Haibach P, Antoch G, Beyer T, et al. FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy. Br J Radiol. 2007;80:508–15.CrossRefPubMed
8.
Costelloe CM, Rohren EM, Madewell JE, et al. Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncol. 2009;10:606–14.CrossRefPubMed
9.
Ohta M, Tokuda Y, Suzuki Y, et al. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy. Nucl Med Commun. 2001;22:875–9.CrossRefPubMed
10.
Yang SN, Liang JA, Lin FJ, Kao CH, Lin CC, Lee CC. Comparing whole body (18) F-2-deoxyglucose positron emission tomography and technetium-99 m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol. 2002;128:325–8.CrossRefPubMed
11.
Liu T, Cheng T, Xu W, Yan WL, Liu J, Yang HL. A meta-analysis of 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with breast cancer. Skeletal Radiol. 2011;40:523–31.CrossRefPubMed
12.
Shie P, Cardarelli R, Brandon D, Erdman W, Abdulrahim N. Meta-analysis: comparison of F-18 Fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer. Clin Nucl Med. 2008;33:97–101.CrossRefPubMed
13.
Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998;16:3375–79.PubMed
14.
Uematsu T, Yuen S, Yukisawa S, et al. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. AJR Am J Roentgenol. 2005;184:1266–73.PubMed
15.
Nakai T, Okuyama C, Kubota T, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging. 2005;32:1253–8.CrossRefPubMed
16.
Hahn S, Heusner T, Kummel S, et al. Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer. Acta Radiol. 2011;52:1009–14.CrossRefPubMed
17.
Ben-Haim S, Israel O. Breast cancer: role of SPECT and PET in imaging bone metastases. Semin Nucl Med. 2009;39:408–15.CrossRefPubMed
18.
Even-Sapir E, Metser U, Flusser G, et al. Assessment of malignant skeletal disease: initial experience with 18 F-fluoride PET/CT and comparison between 18 F-fluoride PET and 18 F-fluoride PET/CT. J Nucl Med. 2004;45:272–8.PubMed
19.
Schirrmeister H, Guhlmann A, Kotzerke J, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol. 1999;17:2381–9.PubMed
20.
Sharma P, Singh H, Kumar R, et al. Bone scintigraphy in breast cancer: added value of hybrid SPECT-CT and its impact on patient management. Nucl Med Commun. 2012;33:139–47.CrossRefPubMed
21.
Eustace S, Tello R, DeCarvalho V, et al. A comparison of whole-body turboSTIR MR imaging and planar 99mTc-methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases. AJR Am J Roentgenol. 1997;169:1655–61.PubMed
22.
Steinborn MM, Heuck AF, Tiling R, Bruegel M, Gauger L, Reiser MF. Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system. J Comput Assist Tomogr. 1999;23:123–9.CrossRefPubMed
23.
Horvath LJ, Burtness BA, McCarthy S, Johnson KM. Total-body echo-planar MR imaging in the staging of breast cancer: comparison with conventional methods—early experience. Radiology. 1999;211:119–28.PubMed
24.
Walker R, Kessar P, Blanchard R, et al. Turbo STIR magnetic resonance imaging as a whole-body screening tool for metastases in patients with breast carcinoma: preliminary clinical experience. J Magn Reson Imaging. 2000;11:343–50.CrossRefPubMed
25.
Tamada T, Nagai K, Iizuka M, et al. Comparison of whole-body MR imaging and bone scintigraphy in the detection of bone metastases from breast cancer. Nihon Igaku Hoshasen Gakkai Zasshi. 2000;60:249–54.PubMed
26.
Lauenstein TC, Goehde SC, Herborn CU, et al. Whole-body MR imaging: evaluation of patients for metastases. Radiology. 2004;233:139–48.CrossRefPubMed
27.
Engelhard K, Hollenbach HP, Wohlfart K, von Imhoff E, Fellner FA. Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer. Eur Radiol. 2004;14;99–105.CrossRefPubMed
28.
Gutzeit A, Doert A, Froehlich JM, et al. Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma. Skeletal Radiol. 2010;39:333–43.CrossRefPubMed
29.
Schmidt GP, Schoenberg SO, Schmid R, et al. Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol. 2007;17:939–49.CrossRefPubMed
30.
Antoch G, Vogt FM, Freudenberg LS, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA. 2003;290;3199–3206.CrossRefPubMed
31.
Schmidt GP, Baur-Melnyk A, Haug A, et al. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT. Eur J Radiol. 2008;65:47–58.CrossRefPubMed
32.
Niikura N, Liu J, Costelloe CM, et al. Initial staging impact of fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced breast cancer. Oncologist. 2011;16:772–82.CrossRefPubMed
Metadaten
Titel
Advanced breast cancer: new imaging techniques for detection of metastases
verfasst von
Helmut Schoellnast, MD
Christian Gstettner, MD
Publikationsdatum
01.06.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0008-1

Weitere Artikel der Ausgabe 2/2012

Breast cancer: is there a need for biopsy of metastases?

  • short review

The role of Positron Emission Tomography/Computer Tomography (PET/CT) in the diagnosis, staging, characterization, and therapy of breast cancer

  • short review

Lung cancer screening: current evidence and recommendations

  • short review

Treatment outcome in AML: a single-centre experience in an unselected patient cohort

  • original report

Immunotherapy for nonsmall-cell lung cancer

  • short review

What’s new in metastatic breast cancer?

  • review